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Abstract 30 
Objective:  We examined associations between the fat-mass and obesity-associated (FTO) 31 
gene (rs9939609) and any weight change over a 5-year period following a 14-week lifestyle 32 
intervention among middle-aged Japanese women.   33 
Materials/Methods:  One hundred twenty-eight Japanese women (BMI >25 kg/m2) 34 
participated in a 14-week weight loss intervention between 2004 and 2006.  Of the 35 
participants, 62 consented to the 5-year follow-up measurement session.  Of these women, 36 
47 women who achieved a weight loss of at least 10% from their baseline values during the 37 
14-week intervention were included in the analysis.  Body weight, body fat, abdominal fat 38 
assessed by CT scans, and metabolic risk factors (i.e., blood pressure, lipids, and glucose) 39 
were measured at baseline, post-intervention, and at the 5-year follow-up.   40 
Results:  During the 5-year non-intervention period, increases in body weight, fat mass, total 41 
abdominal fat, and subcutaneous abdominal fat were significantly greater in subjects with the 42 
homozygous minor allele (AA genotype, n = 4; 8.5%) than in those with the homozygous 43 
major allele (TT genotype, n = 31; 66.0%) or heterozygous allele (TA genotype, n = 12; 44 
25.5%).  In multiple regression analyses, the variation in rs9939609 was a significant and 45 
independent predictor (P <0.001) for regaining weight during the 5-year follow-up.   46 
Conclusions:  Our data suggest that Japanese women with the risk allele (AA) of rs9939609 47 
may have more difficulty preventing fat gain from reoccurring after weight loss intervention 48 
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than women with the other genotypes. 49 
Key words: Abdominal Obesity; Genotype; Lifestyle Intervention; Weight Loss 50 
 51 
List of abbreviations 52 
AA:  homozygous (adenine/adenine) allele 53 
AC:  abdominal circumference 54 
BMI:  body mass index 55 
CT:  computed tomography 56 
DBP:  diastolic blood pressures 57 
SAF:  subcutaneous abdominal fat 58 
SBP:  systolic blood pressures 59 
TA:  heterozygous (thymine/adenine) allele 60 
TAF:  total abdominal fat 61 
TT: homozygous (thymine/thymine) allele 62 
VAF:  visceral abdominal fat 63 
 64 
Introduction 65 
Many studies [1-5] indicate that gene variants in the fat-mass and obesity-associated 66 
(FTO) gene (primarily rs9939609) are associated with obesity traits.  In our recent studies 67 
[6-8], we showed significant associations between rs9939609 and BMI [7], metabolic 68 
syndrome [6], and interventional weight loss [8] among the Japanese population.  Until now, 69 
however, there have been few studies investigating the associations between FTO genotype 70 
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and maintaining long-term body-weight loss after weight-loss intervention.  In the present 71 
study, we examined the association between rs9939609 and 5-year weight maintenance after 72 
an initial 14-week weight loss intervention among middle-aged Japanese women.  We 73 
hypothesized that subjects with the homozygous minor allele (AA) of rs9939609 would be 74 
more likely to increase their body weight than those with other genotypes during the 5 year 75 
non-intervention period.  76 
 77 
Methods  78 
We recruited 128 Japanese women using the JASSO criterion of obesity of BMI > 25 79 
kg/m2 [9, 10] through advertisements in local newspapers to participate in a 14-week weight 80 
loss intervention between 2004 and 2006.  Of the participants, 124 women completed the 81 
14-week intervention.  Of these women, 62 women consented to a follow-up measurement 82 
session at the end of a 5 year non-intervention period.  In this study, because we focused on 83 
maintaining the body weight change long-term after an intervention, we excluded 15 subjects 84 
who did not achieve at least a 10% loss of weight [11] during the 14-week intervention.  85 
Consequently, 47 subjects were included in the final analysis.  The aim and design of this 86 
study were explained to every subject before each gave her written, informed consent.  This 87 
study was conducted in accordance with the guidelines proposed in the Declaration of 88 
Helsinki.  The Ethical Committee of the University of Tsukuba reviewed and approved the 89 
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study protocol. 90 
The 14-week lifestyle intervention program was mainly comprised of dietary 91 
modifications with a physical activity program (90 minutes per session, 12 times in 14 weeks).  92 
Detailed descriptions of the program have been published elsewhere [12].  93 
Anthropometric measurements were performed by a trained laboratory assistant at 94 
baseline, post-intervention, and at the 5-year follow-up.  Body weight was measured once to 95 
the nearest 0.1 kg using a digital scale (TBF-551; Tanita, Tokyo, Japan), and height was 96 
measured once to the nearest 0.1 cm using a wall-mounted stadiometer (YG-200; Yagami, 97 
Nagoya, Japan) with the subjects in underwear and barefooted while fasting in the morning.  98 
BMI was calculated as weight (in kilograms) divided by height (in meters) squared.  AC was 99 
measured directly on the skin at the level of the umbilicus in the standing position.  The AC 100 
measurements were taken in duplicate to the nearest 0.1 cm.  Body composition, recorded as 101 
percentage fat mass, fat mass (kg), and fat-free mass (kg), was assessed by a bioelectrical 102 
impedance analysis (TBF-551; Tanita, Tokyo, Japan).  We acquired CT images for each 103 
subject using a CT scanner (TSX-002A; Toshiba, Tokyo, Japan) in order to calculate TAF, 104 
VAF, and SAF areas.  A single trained technician performed blinded image analyses to 105 
determine the TAF, VAF, and SAF areas using a computer software program (Fat Scan; N2 106 
system, Osaka, Japan).  Detailed descriptions of the CT methods have been published 107 
elsewhere [12]. 108 
5 
 
Blood pressure and biochemical assays of blood were also measured at baseline, post-109 
intervention, and at the 5-year follow-up.  One trained nurse measured SBP and DBP of 110 
subjects at the right arm using a mercury manometer and a standard protocol after the subjects 111 
rested for at least 20 minutes in the sitting position.  A blood sample was drawn from each 112 
subject after a 12-hour fast.  Serum glucose and lipids were assayed by routine automated 113 
laboratory methods [13].  Low-density lipoprotein cholesterol was calculated according to 114 
Friedewald’s formula [14]. 115 
Genomic DNA was prepared from the blood sample of each subject by using Genomix 116 
(Talent Srl, Trieste, Italy).  The rs9939609 allele within the FTO gene was genotyped using 117 
the TaqMan probe (C_30090620_10; Applied Bio-systems, Foster City, CA, USA).  To 118 
investigate the relationship between the measurement values and the rs9939609 genotype, 119 
subjects were assigned to one of 3 categories depending on their genotype:  homozygous 120 
major allele, TT; heterozygous allele, TA; or homozygous minor allele, AA. 121 
 122 
Statistical analysis 123 
Values are expressed as the mean ± standard deviation.  Paired Student’s t tests were 124 
performed to test the significance of value changes measured at baseline, post-intervention, 125 
and at the 5-year follow-up.  We evaluated the differences among the genotypes by a 126 
univariate ANOVA (PROC GLM in the SAS procedure) with adjustments for age, menstrual 127 
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status, and respective baseline values, when appropriate.  Multiple regression analyses were 128 
conducted to determine a combination of predictors for weight change.  The 129 
Hardy-Weinberg equilibrium was assessed using the χ2 test.  The data were analyzed with 130 
the Statistical Analysis System (SAS), version 9.3 (SAS Institute Inc, Cary, NC, USA).   131 
 132 
Results 133 
The rs9939609 variant was in Hardy-Weinberg equilibrium (P = 0.26) and the minor allele 134 
frequency was 0.213 (TT, n = 31, 66.0%; TA, n = 12, 25.5%; AA, n = 4, 8.5%).  Table 1 135 
shows subjects’ characteristics at baseline, post-intervention, and at the 5-year follow-up 136 
among the rs9939609 genotypes.  At baseline, TAF and SAF were significantly greater in 137 
subjects with the AA genotype than in those with the TT or TA genotypes.  At the 5-year 138 
follow-up, we obtained similar but clearer results, i.e., body weight, BMI, AC, fat mass, TAF, 139 
and SAF were significantly greater in subjects with the AA genotype than in those with the 140 
other genotypes.  Table 2 presents changes in measurement values from pre-intervention to 141 
5-year follow-up and from post-intervention to 5-year follow-up by genotype group including 142 
within-group analyses (paired t test) and group-difference analyses (ANOVA).  In the 143 
analyses comparing pre-intervention values with 5-year follow-up values, there was a trend 144 
toward lower body fat-related values at the 5-year follow-up compared to pre-intervention in 145 
all three groups.  The decrease in fat mass was significantly smaller in subjects with the AA 146 
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genotype than in those with the TT or TA genotypes.  The analyses of values from 147 
post-intervention to 5-year follow-up showed most of the fat-related values of all three groups 148 
had significantly increased at the 5-year follow-up.  The increases in body weight, AC, fat 149 
mass, TAF, and SAF were significantly greater in subjects with the AA genotype than in those 150 
with the TT or TA genotypes.  While significant increases were also observed in many of the 151 
blood sample and blood pressure values during this period, no significant differences across 152 
the genotypes were observed.  In multiple regression analyses, the variation in rs9939609 153 
was a significant and independent predictor (P <0.001) for weight change during the 5-year 154 
follow-up when age, menstrual status, and post-intervention body weight were included in the 155 
model as adjusted values.  The rs9939609 genotypes accounted for 19.3% (adjusted R2 = 156 
0.193) of the total body weight change variance. 157 
 158 
Discussion 159 
Our hypothesis is supported by the significantly greater increases in body weight, i.e., 160 
body fat, during the 5 years of non-intervention in subjects with the AA genotype than in 161 
those with TT or TA genotypes.  Previously, we reported that change in body fat during a 162 
14-week lifestyle intervention tended to be smaller in subjects with AA genotype than in those 163 
with other genotypes [8].  The results showed that AA genotype individuals may have more 164 
difficulty reducing body fat than subjects with the other genotypes.  On the other hand, the 165 
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previous study [8] also showed that all subjects, despite their genotype, decreased their body 166 
weight significantly, and we concluded that the gene impact may not be great enough to 167 
change body weight in response to a short-term intervention, and environmental and 168 
behavioral factors may overcome the effects of genes on body-weight reduction.  However, 169 
the present study, over a much longer term, showed a notable association between FTO 170 
genotype and body fat changes.  Fredriksson et al. [15] indicated that the FTO gene may 171 
participate in the central control of energy homeostasis.  It is possible that the subjects with 172 
the AA genotype in our study were unable to control the daily diet needed to maintain their 173 
reduced body weight as well as the subjects with other genotypes could.   174 
Our results are consistent with other recent studies [16, 17].  Karra et al. [16] showed 175 
that AA carriers of rs9939609 have dysregulated circulating levels of the orexigenic hormone 176 
ghrelin and attenuated postprandial appetite reduction.  Woehning et al. [17] showed that the 177 
AA carriers were more likely to regain weight during the weight maintenance period after a 178 
weight-loss intervention.  If medical personnel could use genetic information for obesity 179 
therapy, they could provide a more effective intervention plan for their patients.  FTO gene 180 
may be a useful predictor for body weight maintenance.   181 
Our study did have limitations.  First, sample size was small, and further research is 182 
needed to confirm our results.  However, the frequency for the A allele in this study (21.3%) 183 
is similar to its frequency in the general Japanese population (21.5%) [6], suggesting this 184 
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study’s subjects represent an unbiased population.  Second, attendance rate at the 5-year 185 
follow-up measurement session was low (50%).  Mean body weight of all 47 subjects at the 186 
5-year follow-up (61.5 ± 8.1 kg) was still lower (P <0.01) than the mean pre-intervention 187 
value (67.0 ± 8.6 kg), although it (61.5 ± 8.1 kg) was greater (P <0.01) than the mean 188 
post-intervention value (57.7 ± 7.3 kg).  This suggests that the final analyses in the present 189 
study included many subjects who suppressed body-weight rebound during the follow-up 190 
period.  This situation should be considered in the interpretation of our results.  Third, 191 
while the present study evaluated subjects’ abdominal fat using a single-slice imaging 192 
technique, a multiple-slice imaging technique might be better for detecting VAF change [18]. 193 
In conclusion, our data suggest that middle-aged Japanese women with the risk allele of 194 
rs9939609 may have more difficulty preventing fat gain from reoccurring after successfully 195 
achieving weight loss during an intervention than women with other genotypes.   196 
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Table 1.  Comparisons of measurement values across genotypes of FTO  rs9939609
Age, yr 55.1 ± 7.4 53.0 ± 5.2 46.3 ± 11.1 0.076 55.3 ± 7.5 53.4 ± 5.3 46.8 ± 11.1 0.096 60.3 ± 7.4 58.3 ± 5.5 51.3 ± 11.1 0.071
Height, cm 154.5 ± 5.0 155.9 ± 5.1 160.3 ± 3.8 0.373 154.5 ± 4.8 155.6 ± 5.2 160.0 ± 3.6 0.409 153.7 ± 5.0 154.9 ± 5.3 159.2 ± 3.8 0.548
Body weight, kg 65.0 ± 8.2 68.2 ± 8.2 78.2 ± 1.6 0.115 56.3 ± 6.9 58.9 ± 7.6 65.6 ± 3.5 0.306 59.7 ± 7.1 61.9 ± 8.0 74.5 ± 3.9 0.026
BMI, kg/m2 27.2 ± 2.4 28.0 ± 2.2 30.5 ± 1.4 0.232 23.5 ± 2.0 24.3 ± 2.0 25.7 ± 1.9 0.526 25.2 ± 2.1 25.8 ± 2.6 29.4 ± 1.2 0.030
AC, cm 93.4 ± 7.0 93.1 ± 9.1 104.3 ± 4.2 0.137 84.5 ± 6.0 85.0 ± 8.7 93.2 ± 5.9 0.212 89.4 ± 5.7 89.5 ± 9.8 102.7 ± 4.4 <0.01
Percentage fat mass, % 36.5 ± 4.9 37.2 ± 4.8 45.0 ± 7.7 0.117 28.6 ± 4.4 28.9 ± 3.4 34.8 ± 3.9 0.143 32.7 ± 5.2 34.4 ± 4.6 43.6 ± 1.9 <0.01
Fat mass, kg 24.0 ± 6.8 25.4 ± 4.4 35.2 ± 5.8 0.078 16.3 ± 4.9 17.1 ± 3.6 22.8 ± 3.1 0.270 19.8 ± 5.1 21.5 ± 5.2 32.5 ± 1.9 <0.01
Fat-free mass, kg 41.0 ± 3.2 42.8 ± 6.1 43.1 ± 6.5 0.577 40.0 ± 3.0 41.8 ± 4.9 42.8 ± 3.0 0.327 40.0 ± 3.4 40.4 ± 3.9 42.0 ± 2.9 0.995
TAF area, cm2 357 ± 70 359 ± 66 497 ± 31 <0.01 256 ± 67 263 ± 66 353 ± 44 0.146 280 ± 61 281 ± 93 427 ± 23 <0.01
VAF area, cm2 107 ± 34 92 ± 26 118 ± 28 0.081 77 ± 23 67 ± 21 86 ± 38 0.321 69 ± 26 68 ± 34 81 ± 17 0.619
SAF area, cm2 250 ± 71 267 ± 53 378 ± 23 0.024 179 ± 60 196 ± 51 267 ± 30 0.126 211 ± 58 213 ± 66 346 ± 12 <0.01
SBP, mmHg 123 ± 12 137 ± 24 139 ± 17 0.067 111 ± 13 123 ± 17 122 ± 18 0.033 120 ± 10 130 ± 16 136 ± 22 0.036
DBP, mmHg 80 ± 7 83 ± 10 87 ± 9 0.281 70 ± 8 75 ± 12 77 ± 9 0.230 77 ± 9 81 ± 13 82 ± 17 0.572
TC, mg/dl 239 ± 40 219 ± 30 228 ± 27 0.493 200 ± 38 206 ± 34 184 ± 32 0.791 219 ± 40 217 ± 36 212 ± 43 0.971
HDLC, mg/dl 60 ± 15 63 ± 13 57 ± 6 0.405 60 ± 12 64 ± 8 55 ± 5 0.206 64 ± 17 68 ± 12 55 ± 9 0.393
LDLC, mg/dl 153 ± 35 139 ± 27 147 ± 31 0.550 126 ± 32 128 ± 33 116 ± 30 0.935 136 ± 35 131 ± 31 138 ± 44 0.784
TG, mg/dl 136 ± 116 85 ± 33 120 ± 29 0.471 67 ± 25 69 ± 17 61 ± 10 0.916 94 ± 46 89 ± 40 96 ± 13 0.846
FPG, mg/dl 94 ± 8 107 ± 32 94 ± 8 0.174 88 ± 8 87 ± 6 91 ± 7 0.394 93 ± 8 98 ± 14 104 ± 9 0.104
Values are presented as the mean ± SD 
AC, abdominal circumference; AA, homozygous minor allele carriers of rs9939609; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDLC, high-density lipoprotein cholesterol; 
LDLC, low-density lipoprotein cholesterol; SAF, subcutaneous abdominal fat; SBP, systolic blood pressure; TA, heterozygous allele carriers of rs9939609; TAF, total abdominal fat; TC, total cholesterol; TG, triglycerides; 
TT, homozygous major allele carriers of rs9939609; VAF, visceral abdominal fat
a Values are adjusted for age and menstrual status except for age.
P a
(n = 31) (n = 12) (n = 4)
5-year follow up
TT TA AA
P a
Baseline
(n = 31) (n = 12)
Post-intervention
TT TA AA
(n = 4)(n = 4)
TT TA AA
(n = 31) (n = 12)
P a
Table 2.  Comparison of changes in values from pre-intervention to 5-year follow-up and post-intervention to 5-year follow-up across genotypes of FTO  rs9939609
Group
difference
s
Group
difference
s
P a P a P a P a P a P a
Body weight, kg -5.3 ± 4.3 <0.01 -6.2 ± 4.3 <0.01 -3.7 ± 2.4 0.056 0.099 3.4 ± 3.1 <0.01 3.0 ± 3.9 0.021 9.0 ± 3.3 0.013 <0.01
BMI, kg/m2 -2.0 ± 1.8 <0.01 -2.2 ± 1.7 <0.01 -1.1 ± 0.9 0.088 0.095 1.7 ± 1.3 <0.01 1.5 ± 1.7 <0.01 3.8 ± 1.0 <0.01 <0.01
AC, cm -4.0 ± 4.8 <0.01 -3.5 ± 5.7 0.056 -1.5 ± 2.8 0.364 0.111 4.9 ± 4.7 <0.01 4.5 ± 6.6 0.036 9.5 ± 1.5 <0.01 0.037
Percentage fat mass, % -3.8 ± 5.1 <0.01 -2.8 ± 7.9 0.248 -1.4 ± 7.7 0.739 0.024 4.1 ± 4.5 <0.01 5.6 ± 4.4 <0.01 8.9 ± 3.1 0.011 0.034
Fat mass, kg -4.3 ± 5.3 <0.01 -3.8 ± 5.8 0.043 -2.7 ± 6.6 0.477 0.025 3.4 ± 3.8 <0.01 4.4 ± 3.7 <0.01 9.7 ± 2.8 <0.01 <0.01
Fat-free mass, kg -1.0 ± 2.1 <0.01 -2.4 ± 4.2 0.073 -1.0 ± 5.3 0.723 0.433 0.0 ± 1.6 0.978 -1.4 ± 2.4 0.069 -0.7 ± 2.4 0.578 0.192
TAF area, cm2 -77 ± 68 <0.01 -77 ± 58 <0.01 -70 ± 37 0.032 0.238 24 ± 56 0.024 18 ± 64 0.354 74 ± 43 0.042 0.018
VAF area, cm2 -38 ± 29 <0.01 -25 ± 28 0.014 -38 ± 27 0.068 0.749 -8 ± 24 0.067 1 ± 24 0.870 -5 ± 23 0.667 0.771
SAF area, cm2 -39 ± 51 <0.01 -52 ± 37 <0.01 -32 ± 31 0.127 0.069 32 ± 45 <0.01 17 ± 44 0.217 79 ± 34 0.019 <0.01
SBP, mmHg -3 ± 12 0.127 -7 ± 16 0.151 -3 ± 7 0.527 0.384 9 ± 12 <0.01 5 ± 12 0.193 14 ± 5 0.014 0.169
DBP, mmHg -2 ± 9 0.138 -3 ± 12 0.495 -5 ± 10 0.439 0.959 7 ± 9 <0.01 5 ± 11 0.119 6 ± 8 0.241 0.957
TC, mg/dl -21 ± 36 <0.01 -2 ± 29 0.855 -16 ± 35 0.439 0.749 19 ± 36 <0.01 12 ± 36 0.264 29 ± 26 0.111 0.761
HDLC, mg/dl 4 ± 8 0.013 5 ± 8 0.045 -2 ± 6 0.492 0.333 3 ± 14 0.193 4 ± 8 0.129 0 ± 8 1.000 0.747
LDLC, mg/dl -16 ± 37 0.190 -8 ± 30 0.403 -9 ± 35 0.655 0.941 10 ± 35 0.101 4 ± 33 0.668 22 ± 24 0.166 0.636
TG, mg/dl -42 ± 107 <0.01 4 ± 42 0.772 -24 ± 25 0.152 0.926 27 ± 44 <0.01 20 ± 35 0.069 36 ± 20 0.036 0.776
FPG, mg/dl -1 ± 8 0.480 -8 ± 24 0.252 10 ± 4 0.017 0.077 5 ± 9 <0.01 12 ± 12 <0.01 13 ± 5 0.012 0.123
Values are presented as the mean ± SD 
AC, abdominal circumference; AA, homozygous minor allele carriers of rs9939609; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDLC, high-density lipoprotein cholesterol; 
LDLC, low-density lipoprotein cholesterol; SAF, subcutaneous abdominal fat; SBP, systolic blood pressure; TA, heterozygous allele carriers of rs9939609; TAF, total abdominal fat; TC, total cholesterol; TG, triglycerides; 
TT, homozygous major allele carriers of rs9939609; VAF, visceral abdominal fat
a Paired Student’s t  tests were performed to test the significance of changes in values.
b Values are adjusted for age, menstrual status, and pre-intervention values.
c Values are adjusted for age, menstrual status, and post-intervention values.
TA AA
P b
(n = 31) (n = 12) (n = 4)
Changes from pre-intervention to 5-year follow-up
TT TA AA
P c
(n = 31) (n = 12) (n = 4)
Changes from post-intervention to 5-year follow-up
TT
